127 related articles for article (PubMed ID: 29199705)
1. Outcomes in lung cancer: An experience from routine tertiary care setting.
Thippeswamy R; Patil S; Prashanth P; Sateesh CT; Vittal T; Shashidhara HP; Haridas KM
Indian J Cancer; 2017; 54(1):276-279. PubMed ID: 29199705
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A
Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772
[TBL] [Abstract][Full Text] [Related]
3. A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma.
Jin F; Zhu H; Shi F; Kong L; Yu J
Clin Interv Aging; 2016; 11():167-73. PubMed ID: 26929611
[TBL] [Abstract][Full Text] [Related]
4. Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes.
Hirsh V; Ko A; Pilot R; Renschler MF; Socinski MA
Clin Lung Cancer; 2016 Sep; 17(5):367-374. PubMed ID: 27230605
[TBL] [Abstract][Full Text] [Related]
5. Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
Weiss JM; Pennell N; Deal AM; Morgensztern D; Bradford DS; Crane J; West HJ; Lee C; Pecot C; Stevenson JP; Irvin W; Socinski M; Stinchcombe T; Villaruz LC; Muss HB
Cancer; 2020 Mar; 126(5):1060-1067. PubMed ID: 31943168
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
7. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
Strauss GM; Lynch TJ; Elias AD; Jacobs C; Herbst R; Leong T; Lynch C; Kwiatkowski DJ; Carey RW; Grossbard ML; Skarin AT
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-73-S12-80. PubMed ID: 9331127
[TBL] [Abstract][Full Text] [Related]
8. A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer.
Liu Z; Wei Z; Hu Y; Gao F; Hao L; Fang P; Sun S; Li J; Jiao S
Med Oncol; 2015 Aug; 32(8):216. PubMed ID: 26168982
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
10. Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer.
Macedo-Pérez EO; Morales-Oyarvide V; Mendoza-García VO; Dorantes-Gallareta Y; Flores-Estrada D; Arrieta O
Cancer Chemother Pharmacol; 2014 Oct; 74(4):681-90. PubMed ID: 25059320
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Schneider BJ; Gadgeel SM; Ramnath N; Wozniak AJ; Dy GK; Daignault S; Kalemkerian GP
J Thorac Oncol; 2011 Jun; 6(6):1117-20. PubMed ID: 21512407
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Zappa F; Droege C; Betticher D; von Moos R; Bubendorf L; Ochsenbein A; Gautschi O; Oppliger Leibundgut E; Froesch P; Stahel R; Hess T; Rauch D; Schmid P; Mayer M; Crowe S; Brauchli P; Ribi K; Pless M;
Lung Cancer; 2012 Dec; 78(3):239-44. PubMed ID: 23009726
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.
Sakata S; Saeki S; Okamoto I; Otsubo K; Komiya K; Morinaga R; Yoneshima Y; Koga Y; Enokizu A; Kishi H; Hirosako S; Yamaguchi E; Aragane N; Fujii S; Harada T; Iwama E; Semba H; Nakanishi Y; Kohrogi H
Lung Cancer; 2016 Sep; 99():41-5. PubMed ID: 27565912
[TBL] [Abstract][Full Text] [Related]
14. Weekly vinorelbine and paclitaxel in older patients with advanced non-small cell lung cancer: A phase II Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
Huerter MM; Meza JL; Copur MS; Tolentino A; Marr AS; Ketcham M; DeSpiegelaere H; Kruse S; Kos ME; Swenson K; Radniecki SE; Kessinger A; Ganti AK
J Geriatr Oncol; 2017 Jan; 8(1):18-22. PubMed ID: 27491498
[TBL] [Abstract][Full Text] [Related]
15. A randomized placebo-controlled clinical study of
Wu Y; Feng J; Hu W; Luo Q
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28356484
[TBL] [Abstract][Full Text] [Related]
16. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
18. A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer.
Tanaka H; Taima K; Morimoto T; Tanaka Y; Itoga M; Nakamura K; Hayashi A; Kumagai M; Yasugahira H; Mikuniya M; Okudera K; Takanashi S; Tasaka S
BMC Cancer; 2017 Oct; 17(1):683. PubMed ID: 29037236
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent non-small-cell lung cancer.
Noronha V; Patil VM; Joshi A; Prabhash K
Indian J Cancer; 2013; 50(2):122-7. PubMed ID: 23979203
[TBL] [Abstract][Full Text] [Related]
20. Assessing the clinical outcome of nab-paclitaxel in Chinese patients with advanced non-small-cell lung cancer.
Zeng J; Yin J; Yuan D; Yang W; Liang W; Wu G; Song Y
Clin Respir J; 2017 Sep; 11(5):632-639. PubMed ID: 26404101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
